BIA
ABCL icon

Bell Investment Advisors’s AbCellera Biologics ABCL Stock Holding History

Bell Investment Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-136
Closed -$403 – 1878
2024
Q2 		$403 Buy
+136
New +$515 ﹤0.01% 1866
2023
Q3 		– Sell
-69
Closed -$446 – 1923
2023
Q2 		$446 Buy
+69
New +$471 ﹤0.01% 1878

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bell Investment Advisors's ABCL Position: Q3 2024 in Review

Bell Investment Advisors sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 136 shares — an estimated $403 sold.

Bell Investment Advisors first reported a position in ABCL in Q2 2023 and held it in 2 quarters. The position peaked at $446 in Q2 2023. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Bell Investment Advisors reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
  • Bell Investment Advisors sold 136 AbCellera Biologics shares in Q3 2024, an estimated $403.
  • Bell Investment Advisors first reported a position in AbCellera Biologics in Q2 2023 and held it in 2 quarters.
  • Bell Investment Advisors's AbCellera Biologics position peaked at $446 in Q2 2023.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Bell Investment Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.